Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series
Sean Bentley, Hewa Artin, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon de Peralta, D. Baker, J. Mishra, Dhakshin Ramanathan
Pharmacotherapy February 5, 2022 DOI: 10.1002/phar.2664 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Case report Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine PTSD |
| Key points | The authors state that no data directly compare depression or other comorbidity outcomes between racemic ketamine and intranasal (S)-ketamine, and they note that recent meta-analyses suggest intravenous racemic ketamine may be more potent than intranasal (S)-ketamine. |
Abstract
Racemic (R,S)‐ketamine is a glutamatergic drug with potent and rapid acting antidepressant effects. An intranasal formulation of (S)‐ketamine was recently approved by the US Food and Drug Administration (FDA) to be used in individuals with treatment‐resistant depression (TRD). There are no data directly comparing outcomes on depression or other comorbidities between these two formulations of ketamine. However, recent meta‐analyses have suggested that IV racemic ketamine may be more potent than IN‐(S)‐ketamine.